Skip to main content
QCLS
NASDAQ Life Sciences

Q/C Technologies Q3 Loss Narrows to $0.9M; Discloses 4.98M-Share Warrant Exchange at $0.3101

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.303
Mkt Cap
$2.54M
52W Low
$0.301
52W High
$8.17
52W Position info
0.6% above low
Off High info
96% below high
Rel. Volume
Market data snapshot near publication time

QCLS is trading near its 52-week low of $0.301 (0.6% above the low).

Summary

Q/C Technologies posted a $0.9M Q3 net loss (flattered by a $1.5M non-cash derivative gain) and disclosed a November 15 related-party warrant exchange that issues 4,982,272 shares at $0.3101 and resets preferred conversion and warrant prices to that level.


Key Events · Earnings and Guidance · QCLS

  • Q3 Loss Narrows on Non-Cash Gain

    Net loss was $941,793 versus $2,811,388 a year earlier, but the swing came from a $1,541,000 non-cash gain on remeasuring the Series H derivative liability — not operations.

  • Nine-Month Loss Widens to $11.3M

    The nine-month net loss was $11,313,780 versus $5,732,326, including a $3,177,999 impairment of the terminated LightSolver technology license.

  • Related-Party Warrant Exchange Dilutes

    On November 15, 2026 PharmaCyte exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares at $0.3101, and anti-dilution provisions reset Series G and Series H conversion prices and certain warrant strikes to $0.3101.

  • Liquidity Claimed for Twelve Months

    Cash of $2,585,051 plus $6,805,270 of marketable securities at September 30, 2026; management says resources fund operations for at least twelve months.


Analysis · QCLS · Life Sciences

The quarter looks better than a year ago — a $941,793 net loss versus $2,811,388 — but that improvement is almost entirely a $1,541,000 non-cash gain from remeasuring the Series H derivative liability as the share price fell, not an operating gain. The nine-month picture is worse: an $11.3M net loss that includes a $3.18M write-off of the terminated LightSolver license. More consequential is the November 15 warrant exchange with PharmaCyte, a related party whose interim CEO is Q/C's own Executive Chairman. PharmaCyte swapped 851,304 Series G warrants for 4,982,272 new shares priced at $0.3101 — roughly 58% of the 8.62M shares outstanding — and the anti-dilution ratchets reset the Series G and Series H conversion prices and certain warrant strikes to that same $0.3101. That is real, large dilution layered on top of a stock already trading near its 52-week low and under a Nasdaq bid-price deficiency notice with a May 5, 2027 cure deadline.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, QCLS was trading at $0.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $0.30 to $8.17. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

QCLS - Latest Insights

QCLS
Nov 13, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.3064
Real-time Price: $0.3125 info
Change: +$0.0061 (+2%) info
Market Cap: $2.54M info
QCLS
Aug 12, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.89
Real-time Price: $0.3125 info
Change: -$2.58 (-89%) info
Market Cap: $2.54M info
QCLS
Jul 02, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.92
Real-time Price: $0.3125 info
Change: -$3.61 (-92%) info
Market Cap: $2.54M info
QCLS
May 15, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.48
Real-time Price: $0.3125 info
Change: -$4.16 (-93%) info
Market Cap: $2.54M info
QCLS
May 15, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.60
Real-time Price: $0.3125 info
Change: -$4.29 (-93%) info
Market Cap: $2.54M info